Anti-UGT1A9 Antibody

Raised in rabbits, this unconjugated polyclonal reagent targets UDP-glucuronosyltransferase 1A9, a phase II drug-metabolizing enzyme that conjugates glucuronic acid to phenolic substrates, flavonoids, and several clinically important medications including propofol, mycophenolic acid, and the active irinotecan metabolite SN-38. Distributed by Antibodies.com as a 100 µl aliquot supplied at 1 mg/ml in PBS with 0.1% sodium azide and 50% glycerol, the antibody is validated for western blot, immunohistochemistry, and immunofluorescence workflows, and was shown to react with human, mouse, and rat samples. Each preparation is affinity purified to limit off-target binding, and the included glycerol stabilizer tolerates routine freeze-thaw cycles when material is drawn repeatedly from a single vial. Store refrigerated for short-term use or frozen in working aliquots, protected from light, to preserve activity across multiple experiments. Investigators studying hepatic drug clearance, pharmacogenomic variation in glucuronidation capacity, or xenobiotic metabolism apply this reagent to map UGT1A9 expression in liver tissue, hepatocyte cultures, and tumor-derived cell lines.